Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.
SB4
anti-TNF
biosimilar
drug survival
inflammatory arthritis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Jan 2022
26 Jan 2022
Historique:
received:
21
12
2021
revised:
19
01
2022
accepted:
20
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
We evaluated the 3-year drug survival and efficacy of the biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients, previously treated with etanercept (ETA). Drug survival rate was calculated using the Kaplan-Meier method and Cox proportional hazard models were developed to examine predictors of SB4 discontinuation. 236 patients (120 RA, 80 PsA and 36 AS), aged 60.7 ± 13.8 years and with an ETA duration of 4.1 ± 3.4 years were included. The 3-year retention rate for SB4 was 94.4%, 88% and 86% in AS, RA and PsA patients, respectively, with no difference between groups. Patients without comorbid disease had higher retention rates vs. patients with comorbid disease (90% vs. 60%,
Identifiants
pubmed: 35160074
pii: jcm11030621
doi: 10.3390/jcm11030621
pmc: PMC8837069
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Drug Discov. 2019 Feb;18(2):91
pubmed: 30710137
J Dermatolog Treat. 2020 Nov;31(7):687-691
pubmed: 30985223
Biomed Rep. 2013 Mar;1(2):177-184
pubmed: 24648915
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S14-8
pubmed: 16273780
Br J Clin Pharmacol. 2016 Jul;82(1):64-73
pubmed: 26972584
Ann Rheum Dis. 2017 Aug 9;:
pubmed: 28794078
Ther Adv Musculoskelet Dis. 2020 Oct 13;12:1759720X20964031
pubmed: 33133246
Semin Arthritis Rheum. 2018 Aug;48(1):28-34
pubmed: 29398124
Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-65-74
pubmed: 25365092
Arthritis Rheumatol. 2018 Sep;70(9):1408-1418
pubmed: 29609207
Ann Rheum Dis. 2019 Feb;78(2):192-200
pubmed: 30396903
J Rheumatol. 1994 Dec;21(12):2286-91
pubmed: 7699630
Ther Adv Musculoskelet Dis. 2020 Nov 2;12:1759720X20970028
pubmed: 33224281
Br J Dermatol. 2019 Nov;181(5):1078-1079
pubmed: 31049938
Arthritis Res Ther. 2009;11(3):229
pubmed: 19519924
PLoS One. 2020 Nov 3;15(11):e0241575
pubmed: 33141869
J Clin Med. 2020 Apr 24;9(4):
pubmed: 32344563
Ann Rheum Dis. 2018 Feb;77(2):165-174
pubmed: 28866648
Rheumatol Ther. 2019 Sep;6(3):317-338
pubmed: 31385263
Reumatismo. 2021 Aug 03;73(2):71-88
pubmed: 34342209
Rheumatol Int. 2021 May;41(5):863-877
pubmed: 33175207
Br J Dermatol. 2018 Mar;178(3):e215-e216
pubmed: 29023641
Sci Rep. 2021 May 27;11(1):11091
pubmed: 34045525
Clin Exp Rheumatol. 2018 Sep-Oct;36(5):900-910
pubmed: 29600949
Arthritis Res Ther. 2018 Jul 11;20(1):140
pubmed: 29996916
Ann Rheum Dis. 2014 Jan;73(1):6-16
pubmed: 23749611
Rheumatology (Oxford). 2017 Dec 1;56(12):2093-2101
pubmed: 28968793
Arthritis Care Res (Hoboken). 2016 Sep;68(9):1320-31
pubmed: 26713432
Clin Exp Rheumatol. 2021 Mar-Apr;39(2):365-371
pubmed: 32662409
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Int J Clin Pharm. 2019 Feb;41(1):9-12
pubmed: 30610544
Eur J Clin Invest. 2018 Nov;48(11):e13013
pubmed: 30079593
RMD Open. 2015 Nov 18;1(1):e000155
pubmed: 26629366
Ann Rheum Dis. 2017 Jan;76(1):51-57
pubmed: 26150601